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Background: Although atrial fibrillation (AF) ablation is increasingly used for rhythm 
control therapy, antiarrhythmic drugs (AADs) are commonly used, either alone or in 
combination with ablation. The effectiveness of AADs is highly variable. Prior work 
from our group suggests that alterations in the atrial resting membrane potential 
(RMP) induced by low Pitx2 expression could explain the variable effect of flecainide.  
Objective: This study assessed whether alterations in the atrial/cardiac RMP modify 
the effectiveness of multiple clinically used AADs.  
Methods: The sodium channel blocking effects of propafenone (300nM, 1µM), 
flecainide (1µM) and dronedarone (5µM, 10µM) were measured in human stem cell 
derived cardiac myocytes, HEK293 expressing human Nav1.5, primary murine atrial 
cardiac myocytes and murine hearts with reduced Pitx2c.    
Results: A more positive atrial RMP delayed INa recovery, slowed channel 
inactivation and decreased the peak AP upstroke velocity. All three AADs displayed 
enhanced sodium channel block at more positive atrial RMPs. Dronedarone was the 
most sensitive to changes in the atrial RMP. Dronedarone caused greater reductions 
in AP amplitude and peak AP upstroke velocity at more positive RMPs. Dronedarone 
evoked greater prolongation of the atrial effective refractory period and post-
repolarisation refractoriness in murine Langendorff-perfused Pitx2c+/- hearts, which 
have a more positive RMP compared to wild-type.  
Conclusion: The atrial RMP modifies the effectiveness of several clinically used 
AADs. Dronedarone is more sensitive to changes in atrial RMP than flecainide or 
propafenone. Identifying and modifying the atrial RMP may offer a novel approach to 
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Rhythm control therapy is used in 10-20% of patients with atrial fibrillation (AF) to 
improve AF-related symptoms, often involving antiarrhythmic drugs (AADs) as first-
line therapy1 or in combination with AF ablation2. Although anticoagulation now 
prevents most ischemic strokes in AF patients, the rates of stroke, heart failure, 
unplanned hospitalisations and cardiovascular death remain high1,3. Data suggest 
that restoring and maintaining sinus rhythm in patients with recently diagnosed AF 
provides clinical benefit compared to symptom-directed, selective rhythm control 
therapy4. This clinical benefit was achieved using a treatment strategy comprising 
AADs and AF ablation4. These results enhance the need for widely accessible and 
effective rhythm control therapy.  
 
AADs are readily available in many cardiovascular care settings5, but their 
effectiveness is variable1. Predicting efficacy remains an unresolved clinical 
challenge1,3, and practice patterns suggest that local protocols rather than patient 
factors determine AAD selection5. Methods supporting the selection of effective AAD 
therapy could improve delivery of accessible rhythm control therapy in patients with 
AF6. 
  
An important factor in determining AAD effectiveness is likely to be the underlying 
atrial electrical dysfunction6, including a more positive atrial RMP7. A shift in RMP 
directly modifies the efficacy of the sodium channel blocker flecainide in murine 
atria7. Whether this effect is evident in humanised cardiac cell models has not been 
tested. The effect of a more positive RMP on other AADs with sodium-channel 









cardiac cell models. The aim of this study was to quantify and compare the impact of 
different RMPs on the sodium channel-blocking efficacy of propafenone, flecainide 
and dronedarone in human cardiac cell models, primary murine atrial cells and in 











Full methods are presented in the Supplementary Material.   
 
Ethics and Approval 
Procedures and experiments involving human atrial cells were approved by the West 
of Scotland Research Ethics Service (REC: 17/WS/0134). The human research 
reported in this paper adhered to the Helsinki Declaration. All animal procedures 
were performed in accordance with UK Animals (Scientific Procedures) Act 1986 and 
approved by the UK Home Office (PFDAAF77F). Animal research reported in this 
paper adhered to the ARRIVE and Guide for the Care and Use of Laboratory 
Animals guidelines. Hearts were isolated from wild-type (WT) and Pitx2c+/- male and 
female adult mice (N=77) bred on a MF1 background, by thoracotomy under deep 
terminal isoflurane anaesthesia (4-5% isoflurane in O2, 1.5L.min
-1).  
 
Recordings of sodium currents and action potentials in hNav1.5/SCN1B 
expressing HEK293 cells and hiPSC-CMs 
For sodium currents (INa), whole cell patch clamp recordings were obtained as 
described previously7,8. INa was elicited at 100ms steps to -30mV from holding 
potentials of -100 to -70mV. Currents were measured before and after propafenone 
(Sigma, 300nM or 1µM), dronedarone (Sigma, 5 and 10µM) and flecainide (Sigma, 
1µM). These concentrations are consistent with those previously reported in the 











APs were recorded at 36-37°C in the whole cell current clamp configuration and 
triggered by 2ms current injections (1.5nA). AP trains were stimulated at 1Hz. APs 
were recorded at RMPs -90 to -65mV by varying the background current injection. 
Action potential amplitude (APA) and peak AP phase 0 upstroke velocity (dV.dt-1) 
were analysed using modified algorithms from ElectroMap11.  
 
Recordings of human atrial action potentials 
Right atrial tissue samples were obtained from 6 adult patients undergoing cardiac 
surgery (Supplementary Table 1). Cardiomyocytes were enzymatically isolated from 
this tissue using the ‘chunk’ method12. APs were stimulated and recorded at 35-37°C 
by whole-cell-patch clamp, with an Axon Instruments AxoClamp 2B amplifier and 
WinWCP or WinEDR software (J Dempster, Strathclyde University).  
 
Cell isolation and recordings of sodium currents in primary murine left atrial 
(LA) cardiac myocytes 
Hearts were isolated from wild type (WT) and Pitx2c+/- mice and digested via a 
Langendorff apparatus as described13. Peak INa was recorded as described for 
hiPSC-CMs and HEK293 cells except that a low sodium external solution was used. 
 
Recordings of murine LA transmembrane action potentials (TAPs) 
TAPs were recorded at 37°C from the epicardial surface of WT and Pitx2c+/- LA 
using custom-made glass microelectrodes containing 3M KCl, (resistance 15-20 MΩ) 
as described13,14.  
 









LA MAPs were recorded at 37°C from Langendorff-perfused beating hearts isolated 
from WT and Pitx2c+/- mice as described7. MAPs were recorded over a range of 120, 
100 and 80ms cycle lengths. Programmed stimulation was performed at baseline 
and with dronedarone (Sigma, 10µM).  
 
Data Analysis.  
Values are expressed as mean±SEM. Single cell/heart/patient measurements are 
shown as individual points. Statistical analysis was performed using 1) one-way 
repeated measures Analysis of Variance (ANOVA), 2) a two-way ANOVA with 
Bonferroni post hoc analysis or 3) a paired/unpaired 2-tailed student’s t-test, (Prism8, 












Propafenone and dronedarone inhibit Nav1.5 currents more effectively at more 
positive RMPs 
Analysis of the Genotype-Tissue Expression (GTEx) database identified SCN5A and 
SCN1B as the most highly expressed alpha and beta subunits respectively in human 
atria (Fig 1A). Therefore, the effects of dronedarone and propafenone were 
assessed in HEK293 cells stably expressing SCN5A and SCN1B. For propafenone 
and dronedarone peak INa inhibition progressively increased at more positive 
RMP/VH (Fig 1B-D). This was consistent at both concentrations tested for each AAD 
(Fig 1C & D). Comparison between agents identifies that dronedarone has an almost 
2-fold greater sensitivity (%inhibition per mV increase in RMP/VH) to RMP/VH than 
propafenone (P<0.01;Fig 1E). For both agents the RMP/VH sensitivity was not 
modified by concentration (Fig 1E).  
 
A more positive RMP/VH decreased the peak INa activation time constant, an effect 
that was not further modified by propafenone or dronedarone (Fig 2A-B). More 
positive RMP/VH increased the inactivation time constant, consistent with a slower 
rate of current decay (Fig 2B). Additionally, a more positive RMP/VH significantly 
slowed the time-dependent peak INa recovery rate under control conditions, and in 
the presence of propafenone (300nM) and dronedarone (5µM) (Fig 2C). Comparison 
of the 50% recovery times (P50) demonstrates that neither propafenone nor 











The RMP modifies the human atrial action potential morphology  
In hiPSC-CMs paced at 1Hz, at more positive RMPs (-90 to -65mV) there was a 
graded reduction in both the APA and the peak dV.dt-1 (Fig 3A-C). In primary human 
atrial myocytes paced at 1Hz, current-clamping of the RMP in 5mV steps from -
85mV to -55mV, evoked a marked decrease in the peak dV.dt-1; from ~205V/s at 
RMP -85 mV, to ~25V/s at RMPs of -65mV or more positive (Fig 3D-G). This is 
consistent with voltage-dependent inactivation of INa between -70mV and -60mV, 
and with the corresponding decrease in APA (Fig 3D-G).  
  
Dronedarone causes greater changes in AP morphology at more positive 
RMPs in hiPSC-CMs 
In hiPSC-CMs, control peak INa was progressively reduced as the RMP/VH became 
more positive (e.g. from -5.5±0.5nA at -90mV, to -0.8±0.2nA at -70mV, n=15 cells, 
P<0.001). For propafenone (300nM) and dronedarone (5µM), INa inhibition was 
enhanced at more positive RMP/VH (Fig 4A). The RMP/VH sensitivity of propafenone 
(~1%/mV) was similar to flecainide (1µM), (Fig 4B). Dronedarone inhibition of peak 
INa was 2-fold more sensitive to changes in the RMP (~2%/mV) compared to both 
propafenone and flecainide (Fig 4B).  
 
As dronedarone showed the highest sensitivity to the RMP/VH this agent was taken 
forward for functional testing on hiPSC-CMs. Dronedarone caused APD prolongation 
in the majority of cells, consistent with its known inhibition of IKr, and a reduction in 
both APA and peak dV.dt-1 (Fig 4C-E, Supplementary Fig 1 & 2). The magnitude of 
responses to dronedarone varied at different RMPs. At an RMP of -90mV, 









However, dronedarone caused a greater reduction in APA as the RMP became 
progressively more positive (Fig 4D, Supplementary Fig 1 & 2). Similarly, 
dronedarone more effectively decreased the peak dV.dt-1 at more positive RMPs (Fig 
4E).  
 
Dronedarone causes greater effective refractory period prolongation and post-
repolarisation refractoriness (PRR) in atria with reduced Pitx2c  
Pitx2c+/- LA cardiac myocytes had a more positive RMP and reduced APA 
(Supplementary Fig 3A & B) as expected7. Peak INa was not different between 
genotypes at fixed VH/RMP (Supplementary Fig 3C). Murine LA INa inhibition by 
dronedarone, propafenone and flecainide was enhanced at more positive RMP/VH 
and was similar for both genotypes at fixed VH/RMPs (Supplementary Fig 3D & E).  
 
In isolated, beating mouse hearts, dronedarone (10µM) caused a greater 
prolongation of the LA effective refractory period (ERP) in Pitx2c+/- than in WT 
littermates (Fig 5A & B, Supplementary Fig 4). Dronedarone prolonged APD similarly 
in both genotypes and there were no genotype-dependent differences on activation 
times (AT) (Fig 5C & D). PRR (ERP-APD90) was significantly shorter at baseline in 
Pitx2c+/- LA (Fig 6A & Supplementary Table 2). This effect was abolished after 
treatment with dronedarone (Fig 6B), due to dronedarone causing greater 











A more positive RMP increases the effectiveness of propafenone, flecainide and 
dronedarone in human cardiac cell models and primary murine atrial cardiac 
myocytes. Dronedarone is more sensitive to RMP than propafenone or flecainide. 
Dronedarone-induced PRR is enhanced in atria with a more positive RMP caused by 
a reduction in Pitx2c. Selecting dronedarone or other sodium channel blockers 
based on markers for a more positive RMP and/or as potential companion therapies 
with RMP-depolarising agents in patients with a hyperpolarized RMP emerge as 
promising approaches to improve the effectiveness of AAD therapy for AF.  
 
The atrial RMP modulates the effectiveness of antiarrhythmic drugs. 
Approximately 10-20% of AF patients currently receive rhythm control therapy to 
improve symptoms1. This proportion may increase due to the clinical benefit of early 
rhythm control therapy4, enhancing the need for readily available and effective 
rhythm control therapy. While some patients respond well to AAD therapy, many 
experience early recurrences, with symptomatic AF recurrence occurring in 40-70% 
of AF patients within 6-12 months1. Three of the most used AADs inhibit the cardiac 
sodium channel and were tested here, flecainide, propafenone, and dronedarone.  
 
The present study demonstrates that the RMP modulates the effectiveness of 3 
AADs in human cardiac cell models and murine LA cells. AF has been associated 
with diverse changes in the atrial RMP, including a more negative RMP (~5-









illustrating the heterogenous electrical changes in AF. Variations in different K+ 
currents including IK1, IKACh, IKCa and IKleak
18 can explain these findings. In instances 
where the RMP is altered, our findings would suggest that the extent of this 
modification may be a contributing factor to the overall efficacy of flecainide, 
propafenone and dronedarone.  
 
Previous studies have shown that dronedarone is more effective at blocking INa at 
more positive RMPs in guinea-pig ventricular cardiac myocytes9. Our data shows 
that this effect is consistent in hiPSC-CMs and murine atrial cells. One reason for the 
observed atrial selectivity of dronedarone9 is likely to be the more positive RMP in 
comparison with ventricular myocytes. Our data also shows that dronedarone is 
more sensitive to the RMP than both propafenone and flecainide. The reduced RMP 
sensitivity of flecainide and propafenone in comparison to dronedarone could be a 
contributing factor to their apparent lack of differential atrial/ventricular selectivity19. 
There may be other biophysiological differences that exist between atrial and 
ventricular myocytes that modify drug sensitivity such as alterations in accessory 
subunits, ion channel localisation and post-translational modifications. Although Pitx2 
is expressed in all chambers in the developing heart, in the adult heart, Pitx2 is 
almost completely confined to the LA20,21. While it may be tempting to speculate that 
the difference in RMP between LA and left ventricular cardiomyocytes is due to 
differential Pitx2 expression, other mechanisms must be at play, as right atrial 
cardiomyocytes also have a more positive RMP compared to ventricular 
cardiomyocytes. Our experiments in Pitx2-deficient atria demonstrate that the effect 











Is there a link between a more positive atrial RMP and the genomic markers for 
AF on chromosome 4q25? 
Key single nucleotide polymorphisms (SNPs) on chromosome 4q25, adjacent to the 
PITX2 gene, are by far the strongest genomic signal associated with AF23. PITX2 is 
an important transcription factor that regulates ion channel expression and electrical 
integrity in the adult LA24. The SNPs lie in a region that has putative transcriptional 
enhancer activity of PITX225,26. Risk alleles on chromosome 4q2527 and reduced LA 
PITX2 expression28 are associated with recurrent AF on rhythm control therapy. In 
this study we demonstrate that murine cardiac myocytes with low Pitx2c mRNA 
expression have a more positive RMP, consistent with previous reports7,24, 
suggesting one potential mechanism for this clinical effect. Dronedarone caused 
greater ERP prolongation in Pitx2c+/- atria than in WT, leading to enhanced atrial 
PRR. However, dronedarone did not cause greater APD elongation in either 
genotype. Therefore, we do not think that the exaggerated increase of the ERP in 
Pitx2c+/- deficient atria is due to excessive lengthening of the APD, but instead is 
dependent on an enhanced level of sodium channel block. This is consistent with 
observations from our human and animal cell experiments where sodium channel 
block was elevated at more positive RMPs. It also demonstrates that small 
fluctuations in the RMP can have important functional effects on AAD efficacy. It has 
been reported that flecainide extends the ERP more in Pitx2c+/- hearts compared to 
WT whereas sotalol has no genotype dependent effects7. Collectively, these data 
suggest that both dronedarone and flecainide may provide effective treatment in atria 









whether human atrial cells with reduced PITX2 have a more positive RMP and if they 
respond well to flecainide and/or dronedarone.  
 
Clinical perspective 
There is currently no clinically accessible marker identifying patients with a 
depolarized atrial RMP, although elevated bone morphogenic protein 10 has recently 
been suggested as a blood biomarker for reduced LA PITX228. Drugs depolarizing 
the atrial RMP could be combined with sodium channel blockers such as 
dronedarone to enhance their effectiveness. More research is still required to better 
understand how the RMP is altered by different genetic or environmental causes of 
AF, and clinical markers identifying patients with a depolarized atrial RMP are 
needed to develop and test such therapeutic concepts. 
 
Limitations 
This study utilised murine atrial cardiac myocytes, hiPSC-CMs and HEK293 
expressing human cardiac sodium channels. We also provided validation in perfused 
beating murine atria (Fig 5 & 6). However, we did not perform differentiation 
protocols to generate atrial specific hiPSC-CMs. Validation of the impact of the atrial 
RMP on AAD sensitivities and electrical function specifically in primary human atrial 
tissue is still warranted. There are some limitations with using hiPSCs-CMs due to 
their relatively immature status29. That said these findings showed consistency with 
both primary murine atrial cardiac myocytes and HEK293 cells expressing human 
cardiac Scn5a. Whether the atrial RMP is stable over time and/or whether regional 
variability in the RMP affect atrial function and recurrent AF should be studied in 









surrogates for AAD action, this study could not test whether the RMP has an effect 
on spontaneous or inducible AF. This needs to be addressed in future studies, 
ideally investigating patients and using clinical markers for patients with a more 
positive atrial RMP. The range of drug concentrations used in this study are 
consistent with previous experimental literature7,9,10, are within the range reported to 
inhibit INa and are either within or close to the reported therapeutic plasma 
concentrations. As the exact intra-atrial concentrations have not been reported we 
cannot say for certain that the concentrations used in this study precisely mimic 
those present in vivo at the level of a single atrial cardiac myocyte.  
 
Conclusion 
Dronedarone, propafenone and flecainide are all sensitive to changes in atrial RMP, 
promoting greater peak INa inhibition at more positive RMP. Dronedarone is most 
sensitive to variations in the RMP. In human cardiac cell models dronedarone 
reduces the APA and peak dV.dt-1 to a greater extent at more positive RMPs. 
Dronedarone causes greater prolongation of the ERP and PRR in Pitx2c+/- atria that 
have a more positive RMP compared to WT. Therefore, the RMP is an important 
modulator of the INa inhibiting effect of different clinically used AADs. Targeting the 
RMP to increase the effectiveness of AADs or selecting AADs based on specific 
RMP alterations in different types of AF provide novel approaches for improving 
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Figures and Figure Legends 
 
 
Figure 1. hNav1.5 sodium current (INa) inhibition by propafenone and dronedarone 
is enhanced at more positive resting membrane potentials (RMPs) 
(A) Genotype-Tissue Expression (GTEx) data showing relative mean expression of 
sodium channel genes in the human atrial appendage (N=429 samples). (B) Inhibition 
of INa caused by propafenone (300nM) and dronedarone (5µM) at two different resting 
membrane potentials/holding potentials (RMP/VH).  (C & D) The effect of RMP/VH on INa 
inhibition by propafenone at 300nM (N=15 cells), 1µM (N=8 cells) and dronedarone at 
5µM (N=14 cells) and 10µM (N=8 cells). Data presented as mean±SEM, one-way 
repeated measures ANOVA. (E) RMP/VH sensitivities of propafenone and dronedarone, 










Figure 2. hNav1.5 sodium current (INa) activation, inactivation and time-dependent 
recovery kinetics are sensitive to changes in the resting membrane potential 
(RMP) 
(A) Protocols used to measure INa activation/inactivation time kinetics (upper) and time 
dependent recovery (lower). (B) Activation and inactivation time constants (tau) 
measured at different resting membrane potentials/holding potentials (RMP/VH) for 
control, propafenone (300nM and 1µM, N=23 cells total) and dronedarone (5 µM and 10 
µM, N=21 cells total). One-way repeated measures ANOVA. (C) INa time dependent 
recovery measured in control cells (N=14 cells), propafenone treated (300nM; N=8 
cells) or dronedarone treated (5µM; N=6 cells). (D) Effect of RMP/VH on the Mean 50% 
INa recovery times (P50) for all 3 groups. Data presented as mean±SEM, two-way 



















Figure 3. The resting membrane potential (RMP) regulates the human atrial action 
potential 
(A) Short trains of action potentials (APs) measured at two different RMPs (-85 and -
70mV) in a single human induced pluripotent stem cell derived cardiac myocyte (hiPSC-
CM), paced at 1 Hz. (B & C) Mean data from hiPSCs-CMs (N=18 cells). (D) Short trains 
of APs recorded at two RMPs (-85 and -70mV) in a single primary human right atrial 
cardiac myocyte, paced at 1 Hz. (E) Representative superimposed AP traces recorded 
from a single primary human right atrial myocyte, paced at 1 Hz. The vertical dashed 
cursors show the end of the stimulus and the amplitude of the AP respectively. The peak 
dV.dt-1 was measured between these 2 cursors to avoid the stimulus current. (F & G) 










Figure 4. Dronedarone causes greater inhibition of the cardiac action potential 
amplitude and upstroke velocity at more positive resting membrane potentials 
(RMPs).  
(A) Data from human induced pluripotent stem cells derived cardiac myocytes (hiPSC-
CMs) demonstrating the effect of resting membrane potential/holding potential 
(RMP/VH) on sodium current (INa) inhibition by flecainide (1µM; N=7 cells), propafenone 
(300nM; N=8 cells) and dronedarone (5µM; N=7 cells). (B) RMP/VH sensitivities of 
flecainide, propafenone and dronedarone. **P<0.01, one-way ANOVA with Bonferroni 
post hoc analysis. (C) Action potentials (APs) measured at 3 different RMPs (-100, -90 
& -70mV) measured in a single hiPSC-CM ±dronedarone (5µM), paced at 1 Hz. (D & E) 
Mean data from hiPSC-CMs (N=7 cells). Data presented as mean±SEM, one-way 










Figure 5. Dronedarone causes greater effective refractory period (ERP) 
prolongation in murine left atria (LA) with reduced Pitx2c compared to wildtype 
(A) Monophasic action potentials (MAPs) recorded at 100 ms pacing cycle length from 
wildtype (WT) and Pitx2c+/- intact LA. Added are the action potential duration at 90% 
repolarisation (APD90, blue line) and the ERP (red line) before and after dronedarone 
(10µM). (B-D) Mean effects of dronedarone on the LA ERP, APD70 and activation time 
(AT) in WT (N=6 hearts, 6 animals) and Pitx2c+/- (N=9 hearts, 9 animals), measured at 
120, 100 and 80 ms pacing cycle lengths. Data presented as mean±SEM. * P<0.05 WT 













Figure 6. Dronedarone reverses the shortening of post repolarisation 
refractoriness (PRR) in murine left atria (LA) with reduced Pitx2c  
(A & B) Data showing the PRR before and after dronedarone (10µM) in wildtype (WT, 
N=6 hearts, 6 animals) and Pitx2c+/- (N=6 hearts, 6 animals), measured at 120, 100 and 
80 ms pacing cycle lengths. Data presented as mean±SEM. *P<0.05 WT vs Pitx2c+/-, 
two-way ANOVA with Bonferroni post-hoc analysis.  
Jo
ur
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
